The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.

Gujarat has outperformed the national average (93.23 per cent) in the SDG-3 Index, achieving 95.95 per cent vaccination ...

A recent study confirms that the 100-year-old BCG vaccine does not protect against COVID-19, challenging early assumptions ...

Despite TB’s staggering death toll, Motsoaledi noted that the disease does not receive the same level of public attention as ...

The MHRA will now begin assessing the marketing authorization application (MAA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Guérin (BCG) for the ...

A new study has revealed that a mRNA vaccine against tuberculosis has been shown to effectively boost immunity in pre-clinical trials conducted in mice. According to the researchers, the results ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

Morgan Stanley assumed coverage of CG Oncology (CGON) with an Overweight rating and $55 price target Morgan Stanley sees a competitive profile ...